Cisplatin.
Other.Gemcitabine.[105]Mitomycin.Eribulin mesylate.[106,107]Ixabepilone.[108] Gemcitabine.[105] Mitomycin.
Eribulin mesylate.[106,107] Ixabepilone.[108] Combination regimens that have shown activity in metastatic breast cancer include: AC: Doxorubicin and cyclophosphamide.[109] EC: Epirubicin and cyclophosphamide.[110] Docetaxel and doxorubicin.[111] CAF: Cyclophosphamide, doxorubicin, and 5-FU.[112] CMF: Cyclophosphamide, methotrexate, and 5-FU.[113] Doxorubicin and paclitaxel.[114,115] Docetaxel and capecitabine.[116] Vinorelbine and epirubicin.[117] Capecitabine and ixabepilone.[118] Carboplatin and gemcitabine.[119] Gemcitabine and paclitaxel.[120] There are no data suggesting that combination therapy results in an OS benefit over single-agent therapy.